consists of a standard three-dose primary series (at 2, 4 and 6 months of age) and a booster 4 dose at 12-15 months. Before its introduction into the childhood immunization program, PCV7 was available as a self-financed item and its uptake in the vaccine target population had been low (Ho et al., 2011) . In our locality, the effect of the introduction of PCV7 to the market and before its full implementation through the childhood immunization program upon IPD was recently reported by our group (Ho et al., 2011) . In children <5 years, our data showed that the proportion of PCV7 serotypes had declined from 89.5% in 1995-2001 to 65.7% in 2007-2009 (Ho et al., 2011) . The current study was conducted to assess the changes in serotype distribution and antibiotic resistance of nasopharyngeal isolates prior to and during the early introduction of PCV7 in Hong Kong.
Materials and method

Study design and data collection
Nasopharyngeal specimens were collected from children between 2 and 6 years of age who attend day care centers (DCC) or kindergartens (KG) in Hong Kong during September Kong is divided into 18 school districts, and the sample size of each district was calculated according to the number of DCC and KG places in each district. Ages of children who attend DCC and KG range from 2 to 6 years and 3 to 6 years, respectively. Normally, all children attend 5 days per week for 7 to 9 hours a day in DCC and for 3 to 4 hours a day in a KG. Out of the total of 147,516 DCC and KG places, DCC accounted for 30% while KG accounted for 70%. This ratio was used to calculate the number of children to be recruited from DCC and KG from each district to make the targeted study population of about 2000. Parental and prior hospitalization (past 1 year).
Specimen collection and microbiological methods
A calcium alginate-tipped swab on a flexible aluminum wire (TRANSWAB per nasal; Medical Wire and Equipment Co. Ltd, Corsham, Wilts, England) was used. The specimens were brought back to the laboratory immediately for processing. For selective isolation of S. pneumoniae, swabs were inoculated onto 5% horse blood agar supplemented with gentamicin (2 g/ml) and incubated in 5% CO2 for 16 to 24 hours. All isolates were identified by colony morphology, Gram stain, optochin susceptibility, and bile solubility. Isolates with atypical optocin/bile solubility test results were confirmed by a slide co-agglutination test (Phadebact Pneumococcus Test, Remel).
Susceptibility of the isolates to antibiotics was determined by Etest (AB Biodisk, Solna, Sweden) or the disc diffusion method. The D-test was used to detect inducible resistance to clindamycin. Quality control strains were included on each day of testing. All previously reported but the method do not allow some subtypes to be distinguished (Ho et al., 2004) . Hence, all the isolates (n=163) that could not be identified the serotype level and those that were designated an untypeable at that time were retrieved and tested again by PCR methods (Pai et al., 2006) . PCR assays were used to identify the newly described 6C and 6D serotypes (Ho et al., 2010 ). All serogroup 6 isolates, including those collected in period 1 were tested by PCR assays that could distinguish the 4 subtypes (6A-6D) of serogroup 6
isolates. All isolates were tested in a uniform manner.
Statistical analysis
Data from the two similarly designed studies was pooled and compared. The sampling periods, 1999-2000 (period 1) and 2009-2010 (period 2), were intended to indicate time windows before and after the registration and marketing of PCV7 in Hong Kong, respectively.
The serotype coverage for the 7-valent, 10-valent and 13-valent PCVs for carriage was calculated as the proportion of all isolates included in the vaccine formulations, without taking into account the potential serogroup cross-protection. In view of the demonstrated efficacy of PCV7 for serotype 6A, additional coverage due to this cross protection was also calculated. The Chi square or Student's t test was used to compare participant demographics, pneumococcal carriage rates and serotype frequencies between the two collection periods.
Potential risk factors for carriage of PCV7 were studied by univariate analysis. Variables that were significant in the univariate analysis were further analyzed by logistic regression using the forward-conditional method. The correlation between PCV7 penetration and reduction in 3 
Results
Demographics
There were 1978 and 2211 child participants in period 1 and period 2, respectively.
As shown in Table 1 , there are some differences in the characteristics of the children recruited in the two periods. The average age for period 2 children was significantly younger than that for period 1 children. Four variables were less common among period 2 children: recent antibiotic use, overcrowding, URTI at time of sampling and physician visits. However, about twice as many children had history of prior hospitalization in period 2 than in period 1.
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Serotype distribution
A total of 730 isolates were included in the study, comprising 383 isolates collected in period 1 and 347 isolates in period 2. PCV7 serotypes included 443 isolates, PCV13-nonPCV7 serotypes included 90 isolates and non-PCV13 serotypes included 207 isolates. Table 2 showed the serotype distribution of the isolates according to these PCV categories for the two collection periods. In both collection periods, the three most prevalent serotypes were 6B, 19F and 23F. The prevalence of seven serotypes had significantly changed during the two time periods. The two serotypes that had become less common in period 2 were 14 (8.9% vs.
2.6%, P<0.01) and 18C (2.1% vs. 0.6%, P=0.049). The five serotypes that had significantly increased in prevalence were 19A (0% vs. 2.3%, P<0.001), 6A (3.4% vs. 11.8%, P<0.001), 6C (1.8% vs. 7.8%, P<0.001), 23A (1.6% vs. 5.5%, P=0.003) and 15B (0.3% vs. 2.6%, P=0.007). Table 2 also showed that the serotype coverage of PCV7 had significantly decreased from 66.1% in period 1 to 54.8% in period 2 (P = 0.001). The reduction in the serotype coverage of PCV7 was greater among isolates obtained from younger children. The serotype coverage of PCV7 in period 1/period 2 for children of different ages was as follows: 2 year (94.1%/41.3%), 3 years (69.5%/56.2%), 4 years (69.1%/57.4%) and 5 years (59.8%/54%), respectively. Due to the absence of serotypes 1, 5 and 7F, serotype coverage of PCV7 and PCV10 was the same. The serotype coverage of PCV13 was similar in period 1 and period 2, being 72.6% and 70.6% for all ages, respectively. In period 1, the difference in serotype 9 coverage of PCV7 (66.1%) and PCV13 (72.6%) approached but did not reach statistical significance (P=0.05). In period 2, serotype coverage of PCV13 was 15.9% higher than that of PCV7 (P<0.001, 95% confidence interval for difference, 8.7 -22.8%). However, if complete cross protection against 6A was assumed, the difference in serotype coverage of PCV13 and PCV7 became insignificant (4%, 95% CI -2.9% to 10.9%).
Changes in pneumococcal conjugate vaccine coverage over time
Changes in pneumococcal carriage over time
Overall, the nasopharyngeal carriage rate in period 2 was 15.7% (347/2221) which was lower than that in period 1 (19.4%, 383/1978, P < 0.01). However, the carriage rate of penicillin-nonsusceptibile (Pen-NS) S. pneumoniae in the two periods remained unchanged (11.3% vs. 11.1%, P = 0.8). Table 3 showed that the carriage rate of PCV7 isolates had significantly decreased from 12.8% (253/1978) in period 1 to 8.6% (190/2211) in period 2 (P <0.001). The decline in PCV7 carriage was most remarkable among children aged 2 years (from 27.1% to 7.0%) and 3 years (from 22.7% to 9.1%). The changes among children aged 4 years and 5 years were only modest. After stratification by age, the magnitude of reduction in PCV7 carriage was found to correlate positively with the PCV7 penetration rate (correlate bivariate analysis, Pearson correlation = 0.99, P = 0.01). The carriage rate for PCV13-nonPCV10 types showed a nearly 100% increase from 1.3% (25/1978 ) to 2.5% (55/2211) (P < 0.001). Increases in PCV13-nonPCV10 serotypes were greatest in children aged 2 years but the difference was not statistically significant. The prevalence of non-PCV13 carriage remain To further understand how availability of PCV7 might have affected pneumococcal carriage, the data for children enrolled in period 2 was subjected to univariate and multivariate analyses. Univariate analysis showed that overcrowding had positive correlation with PCV7 carriage (odds ratio [OR] 1.8, 95% CI 1.03-3.2; P=0.04) while a history of PCV7 10 vaccination had negative correlation (OR 0.5, 95% CI 0.3-0.8; P=0.001). The PCV7 carriage rate in children who were age appropriately vaccinated for PCV7 was significantly lower than those who were not (4.8% vs. 9.7%, respectively, P < 0.001). No statistically significant association between PCV7 carriage and the other child characteristics (recent antibiotic use, prior hospitalization, respiratory symptoms at time of sampling, having young siblings aged ≤5 years and recent physician visit) were found. In the logistic regression, a history of PCV7 vaccination was the only variable significantly associated with a lower chance of PCV7 carriage (OR 0.5, 95% CI 0.3-0.7; P=0.001). On the other hand, the carriage rates for PCV13-nonPCV10 (2.2% vs. 2.6%, P = 0.6, respectively) and non-PCV13 (5.2% vs. 4.4%, P = 0.5, respectively) isolates were similar among children who were and were not age appropriately vaccinated for PCV7. 20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   11 time. There was no significant change in nonsusceptibility rate for levofloxacin (0% vs. 0.3%) over time. The capsular serotype of the only isolate with resistance to levofloxacin (MIC 16 g/ml) was 19F.
Changes in antimicrobial susceptibility over time
Stratification by serotype showed that the penicillin and dual penicillin/erythromycin nonsusceptibility rates for serotypes 19F, 14, 6A and 23A had significantly increased over the two time periods. The changes for serotype 6A were most dramatic. The erythromycin nonsusceptibility rates for these serotypes were similar in the two time periods. In period 1, five serotypes (6B, 19F, 23F, 14 and 6C) were often nonsusceptible to both penicillin and erythromycin with rates of 42.9% to 86.5%. In period 2, these serotypes continued to exhibit high rates of dual penicillin/erythromycin nonsusceptibility (59.3% to 100%). Besides these, an additional three serotypes (19A, 6A and 23A) were found to exhibit high rates of dual penicillin/erythromycin nonsusceptibility (75% to 87.8%). No serotype 19A was found in period 1. Six (75%) of the eight serotype 19A isolates found in period 2 were nonsusceptible to both penicillin and erythromycin. PCV7 covered significantly fewer dual penicillin/erythromycin-nonsusceptible isolates collected in period 2 than in period 1 (66% vs. 93.5%, respectively, P<0.001).
Although PCV13 covered more isolates, the serotype coverage for dual penicillin/erythromycin-nonsusceptible isolates in period 2 was still lower than that for period 1 (83.1% vs. 94.0%, respectively, P<0.001). Figure 1 showed a scatter plot of the serotype-specific prevalence with the penicillinnonsusceptibility rates. Curve fitting and linear regression revealed that the two variables had significant associations for both time periods. The correlation coefficient was higher in period 1 (R-square = 0.74, P<0.001) than in period 2 (R-square = 0.43, P<0.001). Weaker but still statistically significant correlations were obtained for erythromycin nonsusceptibility. The 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12 finding showed that antimicrobial resistance could be an important determinant of the serotype prevalence.
Discussion
This study assessed the changes in incidence of pneumococcal carriage, antimicrobial resistance rates and serotype distribution of nasopharyngeal isolates prior to and during early introduction of PCV7 in Hong Kong. The carriage of PCV7 serotypes was found to have declined significantly, especially among younger children in whom the vaccine penetration is higher. This was partially off-set by a slight increase in the non-PCV7 serotypes. The net effect was that children were less likely to carry pneumococci in the latter period. This occurred at a time when the vaccine update was still low (20.4% to 43%) among children aged 2 to 5 years. Consequently, fewer isolates recovered in period 2 were included in the carriage of types included in PCV7 was still high. The types that had declined significantly were serotype 14 and 18C. This may be explained by variations in the vaccine efficacy for the different serotypes (Whitney et al., 2006) . In the Kaiser PCV7 efficacy study, the geometric mean concentration of pneumococcal antibodies was found to be highest for serotype 14, followed by serotype 18C and 6B (Black et al., 2000) . The antibody level concentrations for the remaining serotypes were similar (Black et al., 2000) . Since the vaccine uptake was low, it might take longer for the other serotypes to decrease. While conjugate vaccines confer protection against carriage of types included in the vaccines and occasionally other types in the same serogroups, they provide no protection against serogroups that are not included in the vaccine. Therefore, conjugate vaccine use might be 13 expected to contribute to the observed increase in non-PCV7 types (19A, 6A, 6C, 23A and 15B). Nonetheless, we were unable to demonstrate any association between PCV7 use and carriage of these serotypes.
In our locality, similar temporal changes have also been demonstrated among isolates causing invasive disease in children (Ho et al., 2011) . Among children aged <5 years, the frequencies of serotype 14 and 18C had decreased from 36% to 15.7% and from 4.7% to 0%, (11.1%), South Korea (9.9%), Malaysia (9.1%), and Saudi Arabia (9.0%), but low in Hong Kong (3.1%), Taiwan (4.8%), Thailand (5.2%), the Philippines (1.7%), and Vietnam (0.4%).
It is recognized that antibody induced by the 6B component in PCV7 may provide cross protection against the vaccine-related serotype 6A (Whitney et al., 2006) . However, we found that the prevalence of serotype 6A among nasopharyngeal isolates has increased and were associated with emergence of dual penicillin/erythromycin nonsusceptibility in this serotype.
We have excluded potential confounding with other highly similarly subtypes by using methods that could differentiate 6A from the other closely related 6C and 6D types to analyze all the isolates. Since the strains were antibiotic-resistant, the finding may be partly explainable by selection pressure exerted by heavy antibiotic usage. In southern Israel, increases in multidrug-resistant serotype 6A among Bedouin children have been associated with expansion of ST457 prior to the introduction of PCV7 (Porat et al., 2010) . Future studies to investigate the bacterial population structure underlying the observed increases in the five serotypes (6A, 6C, 19A, 23A and 15B) are warranted.
In conclusion, this study showed that the proportion of several serotypes among pneumococci carried by children in Hong Kong have changed following the availability of PCV7 and to a lesser extent, PCV10 as self-financed items. Although PCV10 was also available in the market, no children enrolled in period 2 reported prior PCV10 immunization indicating its usage at that time was very low. Despite some favorable reduction in the a No PCV10-nonPCV7 serotypes (1, 5 and 7F) were found in both periods. If serotype cross protection for 6B and 6A was assumed, the vaccine coverage for PCV7 and PCV10 in period 1/period 2 was both 69.5%/66.6%, respectively. b For period 1, these included 7C (n=2), 8 (n=1), 13 (n=3), 11A (n=12), 15C (n=7), 15F (n=6), 19B (n=3), 22F (n=1), 28A/F (n=1), 29 (n=1), 33B/C/D (n=2), 34 (n=13), 35AC/42 (n=5), 35B (n=4), 35F (n=2) and nontypeable (n=28). For period 2, these included 8 (n=1), 10A (n=2), 11B/F (n=1), 11D (n=2), 15C (n=23), 15F (n=6), 22F (n=1), 23B (n=1), 29 (n=1), 33B/C/D (n=1), 34 (n=11) 35AC/42 (n=2), 35B (n=2), 35F (n=1), 37 (n=1) and 7C (n=1). 17.0 -a The percentages referred to the proportion of penicillin-nonsusceptible (Pen-NS, MIC >0.06 g/ml), erythromycin-nonsusceptible (Ery-NS) or dual penicillin/erythromycin-nonsusceptible (Pen/Ery-NS) isolates within each serotype group. b The penicillin MIC 50 and MIC 90 for all the isolates were 0.5 g/ml and 2 g/ml, respectively. Forty-nine isolates had penicillin MIC 4 g/ml.
They belonged to 19F (n=35), 23F (n=9), 6B (n=2), 14 (n=1), 15C (n=1) and 19A (n=1). Two isolates had penicillin MIC 8 g/ml (both 19F). 
